BioCentury
ARTICLE | Company News

Aimmune's AR101 gets breakthrough designation

June 19, 2015 1:19 AM UTC

FDA granted breakthrough therapy designation to AR101 from Aimmune Therapeutics Inc. (Brisbane, Calif.) to treat peanut allergy in children and adolescents aged 4-17.

AR101 consists of a standardized complex mixture of 13 naturally occurring peanut proteins, delivered using the company's characterized oral desensitization immunotherapy (CODIT) system. The candidate also has Fast Track designation. ...